Orchestra BioMed Holdings, Inc. reported a second-quarter loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35 and representing an earnings surprise of negative 8.57%. The company posted revenues of $0.09 million for the quarter ended June 2026, falling short of the consensus estimate by 32.31% and down from $0.84 million in the year-ago period. Over the last four quarters, Orchestra BioMed has surpassed consensus EPS estimates twice and topped revenue estimates twice. Shares have added about 2.2% since the start of the year, underperforming the S&P 500's gain of 13.3%. The current consensus EPS estimate stands at a loss of $0.37 on $0.12 million in revenues for the coming quarter and a loss of $1.47 on $0.48 million in revenues for the current fiscal year.
Orchestra BioMed Holdings Inc.Q2 loss per share and revenue missed estimates, with revenue down from year-ago period.
